Lumito (LUMITO) Q1 2025 earnings summary

Executive summary

• Q1 2025 marked by intensified efforts to strengthen financial position and prepare for future growth, including relocation to new cost-efficient premises and strategic partnerships.

• Focus on expanding partnerships, especially with CROs and academic groups, and launching new software for image analysis.

• Enhanced market presence and clarified product messaging to drive sales opportunities.

Financial highlights

• Net sales for Q1 2025 were 0 TSEK, down from 17 TSEK in Q1 2024.

• Net loss after tax was -11,803 TSEK, compared to -7,113 TSEK year-over-year.

• Operating loss was -11,374 TSEK, versus -6,239 TSEK in Q1 2024.

• Cash flow from operations was -6,784 TSEK, a slight improvement from -7,178 TSEK year-over-year.

• Cash and cash equivalents at period end totaled 14,711 TSEK, up from 13,465 TSEK.

Outlook and guidance

• Ongoing focus on building CRO partnerships and expanding into academic and pharma sectors.

• Continued development of "scan-as-a-service" and new software offerings to drive adoption.

• Market trends in digital pathology and precision medicine expected to support long-term growth.